Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 3-Qtr Business Results: 3
February 23, 2009
- PMDA to Take More PE-Based Post-Marketing Safety Measures
February 16, 2009
- Draft Guidance for Biosimilars Explained
February 16, 2009
- Strattera Recommended for Approval for AD/HD
February 16, 2009
- Astellas Withdraws NDA for Controlled-Release Formulation of Tacrolimus in US
February 16, 2009
- FDA Advisory Committee Recommends Approval of Prasugrel
February 16, 2009
- Ministerial Ordinance Issued Prohibiting Online Sale of Class 1, 2 OTC Drugs
February 16, 2009
- Takeda Obtains Approval for Lansoprazole's Successor in US
February 16, 2009
- Low Recognition Rate for AMD: Novartis Survey
February 16, 2009
- New GL Recommends Hp Eradication for All Hp-Related Diseases
February 16, 2009
- Japan's Most Admired Pharma Companies in 2008 P. Reed Maurer
February 16, 2009
- BD Expands Portfolio for Uterocervical Cancer Cytodiagnosis System
February 16, 2009
- 3-Qtr Business Results: 2
February 16, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 16, 2009
- BUSINESS NEWS IN BRIEF
February 16, 2009
- R&D NEWS IN BRIEF
February 16, 2009
- Price Settlement Rate Up to 81.6% in December
February 16, 2009
- NDAs Pending or Expected Soon for 3 Blockbuster Candidates: Novartis
February 16, 2009
- Chugai to Apply for 5 Products in 2009
February 16, 2009
- Takeda Starts PI in Japan for DPP-4 Inhibitor + Actos Combination
February 16, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…